These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 25685067)

  • 1. Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status.
    Genther Williams SM; Kuznicki AM; Andrade P; Dolinski BM; Elbi C; O'Hagan RC; Toniatti C
    Cancer Cell Int; 2015; 15(1):14. PubMed ID: 25685067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers.
    Vilar E; Bartnik CM; Stenzel SL; Raskin L; Ahn J; Moreno V; Mukherjee B; Iniesta MD; Morgan MA; Rennert G; Gruber SB
    Cancer Res; 2011 Apr; 71(7):2632-42. PubMed ID: 21300766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer.
    Vitiello PP; Martini G; Mele L; Giunta EF; De Falco V; Ciardiello D; Belli V; Cardone C; Matrone N; Poliero L; Tirino V; Napolitano S; Della Corte C; Selvaggi F; Papaccio G; Troiani T; Morgillo F; Desiderio V; Ciardiello F; Martinelli E
    J Exp Clin Cancer Res; 2021 Jan; 40(1):15. PubMed ID: 33407715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines.
    Vilar E; Scaltriti M; Balmaña J; Saura C; Guzman M; Arribas J; Baselga J; Tabernero J
    Br J Cancer; 2008 Nov; 99(10):1607-12. PubMed ID: 18941461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of Olaparib (AZD2281) potentiates SN-38 cytotoxicity in colon cancer cells by indirect inhibition of Rad51-mediated repair of DNA double-strand breaks.
    Tahara M; Inoue T; Sato F; Miyakura Y; Horie H; Yasuda Y; Fujii H; Kotake K; Sugano K
    Mol Cancer Ther; 2014 May; 13(5):1170-80. PubMed ID: 24577941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitization of colorectal cancer to irinotecan therapy by PARP inhibitor rucaparib.
    Augustine T; Maitra R; Zhang J; Nayak J; Goel S
    Invest New Drugs; 2019 Oct; 37(5):948-960. PubMed ID: 30612311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent BRAFV600E and BRCA Mutations in MSS Metastatic Colorectal Cancer: Prevalence and Case Series of mCRC patients with prolonged OS.
    Cannon TL; Randall JN; Sokol ES; Alexander SM; Wadlow RC; Winer AA; Barnett DM; Rayes DL; Nimeiri HS; McGregor KA
    Cancer Treat Res Commun; 2022; 32():100569. PubMed ID: 35567913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended microsatellite analysis in microsatellite stable, MSH2 and MLH1 mutation-negative HNPCC patients: genetic reclassification and correlation with clinical features.
    Schiemann U; Müller-Koch Y; Gross M; Daum J; Lohse P; Baretton G; Muders M; Mussack T; Kopp R; Holinski-Feder E
    Digestion; 2004; 69(3):166-76. PubMed ID: 15118395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.
    AlHilli MM; Becker MA; Weroha SJ; Flatten KS; Hurley RM; Harrell MI; Oberg AL; Maurer MJ; Hawthorne KM; Hou X; Harrington SC; McKinstry S; Meng XW; Wilcoxen KM; Kalli KR; Swisher EM; Kaufmann SH; Haluska P
    Gynecol Oncol; 2016 Nov; 143(2):379-388. PubMed ID: 27614696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer.
    Lev A; Deihimi S; Shagisultanova E; Xiu J; Lulla AR; Dicker DT; El-Deiry WS
    Cancer Biol Ther; 2017 Sep; 18(9):694-704. PubMed ID: 28886275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CHFR silencing or microsatellite instability is associated with increased antitumor activity of docetaxel or gemcitabine in colorectal cancer.
    Pelosof L; Yerram SR; Ahuja N; Delmas A; Danilova L; Herman JG; Azad NS
    Int J Cancer; 2014 Feb; 134(3):596-605. PubMed ID: 23873170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity.
    Smeby J; Kryeziu K; Berg KCG; Eilertsen IA; Eide PW; Johannessen B; Guren MG; Nesbakken A; Bruun J; Lothe RA; Sveen A
    EBioMedicine; 2020 Sep; 59():102923. PubMed ID: 32799124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
    Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
    BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homologous Recombination Deficiency Testing to Inform Patient Decisions About Niraparib Maintenance Therapy for High-Grade Serous or Endometrioid Epithelial Ovarian Cancer: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2023; 23(5):1-188. PubMed ID: 37637244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of mismatch repair or microsatellite status on the prognosis and efficacy to chemotherapy in metastatic colorectal cancer patients: A bi-institutional, propensity score-matched study.
    Yao YC; Jin Y; Lei XF; Wang ZX; Zhang DS; Wang FH; Li YH; Xu RH; Wang F
    J Cancer; 2022; 13(9):2912-2921. PubMed ID: 35912009
    [No Abstract]   [Full Text] [Related]  

  • 16. Prognostic value of the combination of microsatellite instability and
    Yang Y; Wang D; Jin L; Wu G; Bai Z; Wang J; Yao H; Zhang Z
    Cancer Manag Res; 2018; 10():3911-3929. PubMed ID: 30310312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of single-source dual-energy CT imaging for discriminating microsatellite instability from microsatellite stability human colorectal cancer.
    Wu J; Lv Y; Wang N; Zhao Y; Zhang P; Liu Y; Chen A; Li J; Li X; Guo Y; Wu T; Liu A
    Eur Radiol; 2019 Jul; 29(7):3782-3790. PubMed ID: 30903331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ.
    Kikuchi T; Mimura K; Okayama H; Nakayama Y; Saito K; Yamada L; Endo E; Sakamoto W; Fujita S; Endo H; Saito M; Momma T; Saze Z; Ohki S; Kono K
    Oncol Lett; 2019 Dec; 18(6):5977-5985. PubMed ID: 31788072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptome and Network Dissection of Microsatellite Stable and Highly Instable Colorectal Cancer.
    Akbari V; Kallhor M; Mollashahi B; Movafagh A
    Asian Pac J Cancer Prev; 2019 Aug; 20(8):2445-2454. PubMed ID: 31450919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of the MAP kinase phosphatase DUSP4 is associated with microsatellite instability in colorectal cancer (CRC) and causes increased cell proliferation.
    Gröschl B; Bettstetter M; Giedl C; Woenckhaus M; Edmonston T; Hofstädter F; Dietmaier W
    Int J Cancer; 2013 Apr; 132(7):1537-46. PubMed ID: 22965873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.